-
FDA grants orphan drug designation to ligufalimab for AML
19 Sep 2025 02:12 GMT
… pancreatic cancer.
The FDA has granted orphan drug designation to ligufalimab, a … azacitidine, decitabine or low-dose cytarabine for patients aged 75 years … intensive chemotherapy.
Orphan drug designation is given to treatments for rare diseases …
-
Ligufalimab Gains FDA Orphan Drug Status for Acute Myeloid Leukemia
17 Sep 2025 19:48 GMT
… Food and Drug Administration (FDA) for the treatment of acute myeloid … chemotherapy.
Early clinical trials have also shown positive … drugs such as Vidaza, Dacogen (decitabine), or low-dose cytarabine … nor doctors know who is receiving which treatment, helping …
-
Actively Recruiting Trials for Lung, Biliary, AML and Small Cell Cancer
16 Sep 2025 02:09 GMT
… clear information about new treatment options. Recent updates include … MAIA Biotechnology.
This phase 2 THIO-101 trial result … company.
The trial is testing Annamycin combined with cytarabine, known … Interactions in Oncology Clinical Trials” by Dr. John Doe …
-
Akeso's Ligufalimab (CD47 mAb) Receives FDA Orphan Drug Designation for Acute Myeloid Leukemia (AML)
16 Sep 2025 03:24 GMT
… Drug Designation (ODD) by the U.S. FDA for the treatment … decitabine, or low-dose cytarabine for newly diagnosed AML … fluctuations; the impact of pharmaceutical industry regulation and health … candidates have entered clinical trials (including 15 bispecific…
-
Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial
09 Sep 2025 12:45 GMT
… A of the trial to receive high dose cytarabine (HiDAC) … and Orphan Drug Designation from the FDA for the treatment of … Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical … to conduct its clinical trials as described in this …
-
Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia
08 Sep 2025 12:30 GMT
… A of the trial to receive high dose cytarabine (HiDAC) … and Orphan Drug Designation from the FDA for the treatment of … Biotech, Inc. Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical … to conduct its clinical trials as described in this …
-
Outlining Historical Standards for Treatment in Newly Diagnosed CML
06 Sep 2025 00:09 GMT
… of care prior to the FDA approval of imantinib (Gleevac … inhibitors (TKIs) for the treatment of this patient population.
Toxicities … combined with low doses of cytarabine, and the other was … for Drug Evaluation and Research: Application Number: NDA 21-335. FDA. …
-
The Role of The Xihuang Pill in Inhibiting Triple-Negative Breast Cancer Through Immunogenic Cell Death
05 Sep 2025 13:47 GMT
… development of this medicine.Keywords: Xihuang pill, triple-negative … kinds of conjugate cytarabine and bile acids, … improve dendritic cell-based vaccines for lymphoma immunotherapy. … its cellular localisation following drug treatment. Cell Stress Chaperones. …
-
How Philadelphia scientists turn toxic fungi, snake venom, and trees into medicine
03 Sep 2025 17:08 GMT
… popular prescription drugs.
Scientists would often find these medicines through trial-and-error … as effective as two FDA-approved leukemia drugs, cytarabine and daunorubicin, according to …
-
Natural Products From Traditional Chinese Medicine: Potential Therapeutic Agents in Cancer Therapy-Induced Cardiotoxicity
02 Sep 2025 16:45 GMT
… progress of modern medicine and biotechnology, the research … pharmaceuticals or possible therapeutic targets for CTIC treatment … . Furthermore, randomized trials and meta-analyses … drugs (5-fluorouracil, 6-mercaptopurine, A2O3, taxanes, cytarabine, …